1 **Does maternal immunization blunt the effectiveness of pertussis vaccines in**
2 **infants? Too early to tell**
3

4 Michael Briga[a], Elizabeth Goult[a], Tobias S Brett[b,c], Pejman Rohani[b,c], Matthieu Domenech
5 de Cellès[a]
6
[a]Infectious Disease Epidemiology Group, Max Planck Institute for Infection Biology,
Berlin, Germany
[b]Odum School of Ecology, University of Georgia, Athens, GA 30602
[c]Center of Ecology of Infectious Diseases, Athens, GA 30602

Abstract

Pertussis, a highly contagious respiratory infection primarily caused by the bacterium
Bordetella pertussis, remains a public health priority largely because of the persistently
high disease burden in infants too young to be vaccinated. To protect this vulnerable
demographic, maternal immunization during pregnancy has been adopted in an
increasing number of countries over the last decade. Although this strategy is effective at
protecting unvaccinated newborns, it has been demonstrated to cause immunological
blunting, whereby maternal antibodies reduce the infant's immune response to pertussis
vaccines. However, the clinical and epidemiological consequences of immunological
blunting remain unclear. To illuminate these consequences, we first reviewed the
epidemiological evidence for the blunting of vaccine effectiveness after primary
immunization of infants. Of the four studies identified, all had short-time monitoring
(range: 2–6 years), and their results were heterogeneous, with some estimates consistent
with blunting. Next, to better interpret this epidemiological evidence, we extended a
previously validated model of pertussis transmission by incorporating maternal
immunization with varying degrees of blunting, assumed to reduce the vaccine
effectiveness in infants born to vaccinated mothers. Our simulations show three results.
First, we find evidence for a transient phase lasting at least a decade after the start of
maternal immunization, during which the long-term epidemiological impact of blunting
is masked. Hence, ignoring these transient dynamics results in an overestimation of the
effectiveness of maternal immunization. Second, because of this transient effect, we show
that current empirical estimates may be consistent with a modest level of blunting,
amounting to a 10–20% reduction in vaccine effectiveness. However, the large between-
study heterogeneity and within-study statistical uncertainty preclude a definitive
conclusion, urging for more research to infer the degree of blunting, if any. Ultimately, we
predict that, regardless of the degree of blunting, maternal immunization remains
effective at reducing pertussis in unvaccinated newborns, supporting the continued use
of this strategy to protect this vulnerable population. More generally, our results suggest
that maternal immunization can result in an infection-control trade-off between age
groups, of practical relevance to many other vaccine-preventable diseases.

Introduction

Pertussis is a highly transmissible respiratory infection that is primarily caused by the bacterium *Bordetella pertussis* [1,2]. Pertussis was a leading cause of childhood mortality until intense immunization programs starting from the 1940s onwards, reduced pertussis notifications by over 90% in many countries [3]. However, in the last couple of decades, pertussis has re-emerged in many populations with high long-term immunization coverage, for reasons which remain highly debated [4].

Newborns are the demographic most vulnerable to pertussis. In high-income countries, pertussis-related hospitalization rates in infants under 6 months are between 100 and 100,000 per year [5], and data from the US [6] and Australia [7] show that over 60% of pertussis-associated hospitalizations are under one year old. To reduce the burden of pertussis in vulnerable newborns, many countries have recently introduced maternal immunization—*i.e.*, vaccinating pregnant individuals, usually during the second or third trimester of pregnancy, with a low-dose tetanus toxoid, diphtheria toxoid, and acellular pertussis (Tdap) vaccine. In 2015, the World Health Organization (WHO) issued an official recommendation for maternal immunization against pertussis [8], and by 2020 maternal immunization against pertussis was recommended in 55 countries [9].

Maternal immunization is highly effective at protecting newborns, with estimates of reductions in pertussis incidence ranging from 70 to 95% [10–14]. However, the downstream consequences of maternal immunization, when infants receive their routine pertussis vaccines, are not well understood. Specifically, there has been long-standing concern regarding potential immunological blunting, *i.e.*, the interference of maternally-transferred antibodies with the infant immune response [15,16]. Indeed, several studies and meta-analyses have shown that, after infants received their primary immunization, the antibody concentrations against several pertussis antigens were reduced by 25%–50% in infants from vaccinated mothers relative to infants from unvaccinated mothers [17–19]. Similarly, the avidity of pertussis antibodies is reduced in infants from vaccinated mothers [20]. Interestingly, the blunting response following maternal pertussis immunization appears to be heterologous, also causing decreased antibody concentration after infants received a polio vaccine [21] and the blunting response also

applies to other vaccines that contain (modified) diphtheria or tetanus toxins as carrier proteins, such as pneumococcus conjugate vaccines and *Haemophilus influenzae* type b vaccine [21].

While immunological blunting is well documented, because maternal immunization was implemented only recently, the consequences of blunting on vaccine effectiveness and the ensuing epidemiology of pertussis remain poorly evaluated. Especially, the recent rollout of maternal immunization and associated short-term epidemiological data make it difficult to detect long-term transmission impacts. Here, we assess the epidemiological evidence for blunting, which we interpret in two steps. First, we review the epidemiological literature for estimates of the impact of maternal immunization on the risk of contracting pertussis after the infant's primary pertussis immunization, which usually consists of two or three vaccine doses given between the ages of two or three months until six months (Table S1, [22]). Second, we extend a previously validated model of pertussis immunization [3,23] to simulate the *long-term* epidemiological impact of maternal immunization with various levels of blunted protection and maternal immunization coverages on the age-specific time series of pertussis incidence. Our study shows that following the implementation of maternal immunization, there is a transient "honeymoon" phase lasting at least a decade [24]. Ignoring these transient dynamics, as is the current practice in empirical studies, results in an overestimation of the effectiveness of maternal immunization. Comparing our model predictions with the results of epidemiological studies, we find that the available empirical estimates, though largely heterogeneous, may be consistent with a modest (10–20%) blunting of vaccine effectiveness in infants born to vaccinated mothers. Even so, we predict that maternal immunization remains effective at reducing pertussis in unvaccinated newborns. Hence, our results support the continued use of maternal immunization to protect this vulnerable population but highlight a potential infection-control trade-off associated with this strategy.

Methods

Literature search for empirical studies on the relative risk of contracting after maternal immunization

To search the literature, we started with the first two studies that estimated maternal

immunization effectiveness on pertussis incidence among children who received at least

one dose of primary immunization [11,12] and went through all peer-reviewed studies

citing these articles using Google Scholar on August 26, 2022 (Fig. 1). To be included in

our overview, studies had to provide an estimate of the effectiveness of maternal

immunization or of the relative risk (RR) of contracting pertussis in infants having

received their primary series of pertussis vaccines from vaccinated vs. unvaccinated

mothers.

Simulation: Model schematic

We implemented an age-structured model of pertussis transmission, extending a

previous model empirically validated on data from Massachusetts, USA [3]. In brief, the

model is based on the Susceptible-Exposed-Infected-Recovery (SEIR, Fig. S1) model in

which pertussis vaccines can fail by (i) failure in "take" (primary vaccine failure) and (ii)

failure in duration (waning of vaccine protection) [25]. Based on immunological evidence

showing an immediate reduction in the antibody response to primary vaccination [17–

19], we assumed that blunting from maternal immunization increased the probability of

primary vaccine failure. Previous results in [3] found no evidence for failure in degree (or

leakiness), and hence we ignored this possibility.

The model is designed such that we follow individuals according to their immunization

history (Fig. S1), starting from their mother's immunization status during pregnancy,

followed by an infant immunization schedule that resembles that of the empirical studies

in Table S1: the infant's primary immunization occurs at the age of three months and an

infant booster at the age of 1.5 years. Newborns can be born in three possible

compartments: from vaccinated mothers whose immunization succeeded, mothers

whose immunization failed, or unvaccinated mothers. Each of these compartments is

followed by a compartment for successful primary infant immunization (Fig. S1) and a

compartment for failed primary infant immunization, thereby becoming susceptible (Fig.

S1). Following the first booster, these susceptibles become immunized again at an

effectiveness of 96%, with a subsequent waning rate of vaccine protection of 0.011 yr^{-1}

(Table S3).

Model parametrization

Our model is based on [3], which was fitted to pertussis incidence data from

Massachusetts to identify the model parameters that best characterized the data. Hence,

for the parameters consistent between both models, we used the estimates from ([3],

Table S3).

By adding maternal immunization to this model, we also added three new parameters.

The first parameter is maternal immunization coverage, for which empirical studies

showed a range between 50% and 90% (Table S1). The second parameter is the duration

of maternally derived immunity, for which, to the best of our knowledge, there are no

empirical estimates. One proxy is the half-life of maternal antibodies, which ranges

between 29 and 36 days [26,27], suggesting that the duration of maternally-derived

immunity is short. However, because of the absence of definite correlates of protection

[28–30], the correspondence between the waning rate of maternal antibodies and that of

maternal immunity is unknown. For example, if both waning rates are assumed equal,

according to our model the effectiveness of maternal immunization in the first two

months after birth would be close to 50% (Fig. S1). This is in contrast with the estimated

effectiveness of maternal immunization in that age class, which ranged from 78% (95%

CI: 48–90; [13]) to 93% (95% CI: 81–97, [10]). Thus, in our model, we calibrated the

average duration of maternal protection to reach these empirical estimates of vaccine

effectiveness. Here we show results with an average duration of 8.7 months (Table S3,

Fig. S2), with variation in the average durations ranging from 4 months to 12 months (Fig.

S7, Fig S8). The third parameter is the blunting of infant immune protection, defined as

the relative reduction in the effectiveness of the primary series in infants born to

vaccinated mothers (compared to infants born to unvaccinated mothers). In simulations,

we considered blunting levels ranging from 0% (no blunting) to 20%.

Estimation of relative risk of infection following maternal immunization

To connect the model outputs with the empirical estimates of relative risk (RR)
[11,12,14,31], we calculated the risk of contracting pertussis in infants born to vaccinated
mothers relative to that of infants born to unvaccinated mothers using the same approach
as in [11,31]. These studies used the screening method following [32], in which the RR is
estimated as:

178
$$RR = \frac{PCV}{(1 - PCV)} \cdot \frac{(1 - PPV)}{PPV}$$

where PCV is the proportion of cases in infants vaccinated born to vaccinated mothers
(among all cases in infants vaccinated) and PPV the proportion of mothers vaccinated
(maternal immunization coverage). The RR is a number greater than or equal to zero,
with (i) 0 indicating no infections in infants of vaccinated mothers and hence a 100%
effectiveness of maternal immunization, (ii) a value of 1 reflecting that infants from
vaccinated and unvaccinated mothers have an equal risk of contracting pertussis, hence
maternal vaccination having no effect on the protection against pertussis in infants, and
(iii) a value above 1 indicating that infants from vaccinated mothers have an increased
risk of contracting pertussis relative to infants from unvaccinated mothers. We validated
the RR estimates of the simulations by setting the half-life of maternally derived
protection to infinity, which resulted in 5% RR in newborns (Fig. S2), matching the initial
95% effectiveness of maternal immunization against pertussis in unvaccinated newborns
fixed in the simulations (Table S3). Hence, while the screening method may have several
limitations in real-world settings [33], it provided reliable estimates of vaccine
effectiveness in the context of our model.

Numerical implementation

We represented the process model as a continuous-time Markov process, approximated
via the tau-leap algorithm [34] with a fixed time step of 1 day. To compare the model
outputs to empirical estimates, we also added an observation model for the RR. This was
done by sampling the number of vaccinated cases born to vaccinated mothers from a
Binomial distribution with probability PCV and size equal to the sample size of each
empirical study. The model was implemented and simulated using the 'pomp' package v.
4.4.3.0 [35], operating in R v. 4.2.0 [36].

Results

Empirical estimates

We identified 276 articles and, after removing 44 duplicate records, screened 232 abstracts (Fig. 1). Our search resulted in five estimates from four studies, with two studies carried out in the UK, one in Australia, and one in California, US (Fig. 2, Table S1). In all studies, maternal immunization coverage was low right after the implementation of maternal immunization but increased to reach >80% (mean: 83%; range: 80%–87%) within two to six years (Table S1). These studies showed that the protective effect of maternal immunization decreased with increasing doses during the infants' primary immunization (Table S1). After the first dose, the RR was low at an average of 0.3, ranging from 0.2 (range of 95% CI lower bounds: 0.1–0.4) to 0.7 (range of 95% CI upper bounds: 0.3–1.8; Fig. 2). After the second or third dose of infant primary immunization, the average RR was 1, with estimates ranging from 0.3 (95% CI: 0.1–0.95) to 1.2 (95% CI: 0.3–2.9; Fig. 2).

The model recapitulates the historical trends of pertussis, with a resurgence caused by a honeymoon effect

To assess the historical impact of routine immunization in infants, we first examined the trends in overall incidence and age-specific susceptibility. Infant immunization induced a strong decrease in pertussis incidence but was followed by a rebound with a gradual buildup of susceptible individuals in adult age groups until a new equilibrium—with lower incidence than in the pre-vaccine era—was reached several decades later (Fig. 3 A & B). As we previously demonstrated in the US, this resurgence was explained as an "end-of-honeymoon" effect, a predictable consequence of incomplete immunization with imperfect but highly effective vaccines. Hence, our model recapitulated the historical dynamics of pertussis in the US, characterized by a resurgence and shift of infections to adolescent and adult age groups [3].

Transient dynamics after the start of maternal immunization

Second, we examined the impact of maternal immunization, which we introduced 100

years after the rollout of infant immunization, to disentangle the consequences of the two

immunization programs. Maternal immunization had the intended effect of decreasing

susceptibility to infection in unvaccinated newborns aged 0–2 mo (Fig. 3B). However,

after the start of maternal immunization, the model predicted a transient phase with

lower pertussis incidence, lasting at least 5 years and followed by a rebound (Fig. 4A). In

newborns, the predicted incidence of pertussis was higher in a scenario with blunting

relative to without blunting, but it always remained lower than before the start of

maternal immunization (Fig. 4A). Thus, maternal immunization was predicted to be

effective at protecting unvaccinated newborns, with benefits by far outweighing any

possible blunting-mediated increases in incidence.

By contrast, in the second age class of infants aged 3–18 mo, (i.e, after receipt of the

primary pertussis immunization), maternal immunization was followed by a decrease of

pertussis incidence, but only when blunting was low (<10%, Fig. 4B). At higher levels of

blunting, pertussis incidence was predicted to increase relative to before the start of

maternal immunization (Fig. 4B). However, the second age class also showed a clear

transient phase, lasting at least 5 years. During this transient phase, pertussis incidence

was first predominantly driven by infants from unvaccinated mothers (Fig. 4C), followed

later on by incidence in infants from vaccinated mothers, who dominated once incidence

had reached equilibrium (Fig. 4D). These dynamics persisted in children up to 5 years of

age, but dissipated by age 10 years, after which pertussis incidence remained low and the

effects of both maternal immunization and blunting on pertussis incidence were

negligible (Fig. S3).

Comparison with empirical estimates suggests that blunting cannot be ruled out

Lastly, we estimated the impact of blunting on the RR of pertussis in vaccinated infants

born to mothers vaccinated during pregnancy. In newborns, our simulations show that

estimates of the effectiveness of maternal immunization (*i.e.*, based on incidence) have a

transient phase in a direction consistent with those deduced from the transient incidence

dynamics: the effectiveness was high at first but decreased with time, and equilibrium

values were reached only after a transient phase that lasted at least a decade (Fig. 5A).

Hence, ignoring the transient dynamics results in an overestimation of the effectiveness of maternal immunization, an effect most pronounced during the first decade after implementation.

As expected, in the second age class of infants aged 3–18 mo, (*i.e.*, after receipt of the primary pertussis immunization), blunting resulted in RR equilibrium values above 1 (*i.e.*, a higher risk of pertussis in infants born to vaccinated mothers), which increased with the input blunting strength. However, these risks were reached only after a transient phase that lasted more than a decade (Fig. 5B). During this transient phase, even in scenarios with blunting, the RR was initially far below 1 and gradually increased after the start of maternal immunization. Hence, ignoring these transient dynamics and assuming that a RR of 1 indicates no blunting may result in overestimating the effectiveness of maternal immunization in both unvaccinated newborns and vaccinated infants (Fig. 5B). It is noteworthy that the transient phase for the estimation of RR or vaccine effectiveness (Fig. 5 A & B) is longer than for the incidence (Fig. 4 A & B). This is because RR and VE are cumulative estimates instead of instantaneous estimates such as incidence (Fig. S4). Interestingly, depending on the contact matrix, the incidence during the transient phase showed oscillating dynamics, which increases the variability between estimates that are done after 3, 6, or even 10 years (Figs. S12, S13), but these oscillations disappeared in the RR estimates (Figs. S14, S15), likely thanks to their cumulative nature. Interestingly, after the transient phase, a scenario without blunting resulted in RRs below one, due to residual protection from maternal antibodies in infants who were vaccinated but in whom the vaccine did not take. This result suggests that the usual assumption that a RR of 1 indicates no blunting may be too optimistic.

Comparing our model predictions with the results of epidemiological studies, all current empirical RR estimates fell well within the transient phase of our simulations (Fig. 5C). Demographic stochasticity accounted for some of the variability in the predicted RR (Fig. 5B), but observation noise due to small sample sizes was by far the largest source of uncertainty (Fig. 5C). Inspecting the overlap between confidence intervals, all the empirical estimates were consistent with blunting, even though two estimates (in the UK and California) were also consistent with no blunting. Hence, according to our simulations, current empirical studies cannot yet detect the eventual epidemiological

consequences of blunting (Fig. 5B), and the model-data comparison suggests that a
modest level of blunting cannot be ruled out (Fig. 5C).

Sensitivity analysis

We checked the sensitivity of our results to variations in five parameters: (i) maternal
immunization coverage, ranging from 50% to 90% (Fig. S5, S6); (ii) average duration of
maternal protection, ranging from 4 months to 1 year (Fig. S7, S8); (iii) beginning primary
immunization at 2, 4 and 9 months (Fig. S9, S10); (iv) different social contact matrices
from 8 European countries, as described in the surveys by [37,38] (Fig. S11-S16); and (v)
with the maternal immunization program starting 60 years after the infant immunization
program, as was the case in many countries (Fig. S17, S18). In our simulations, variation
in these parameters had a substantial impact on pertussis incidence but did not affect the
temporal dynamics in RR following maternal immunization (Fig. S5-S18). Another
noteworthy result was that a considerable reduction of the blunting effect was predicted
when delaying the age at the start of the infant's primary immunization by a few months
(Fig. S9, S10). Hence, our main results were, on the whole, robust to assumptions about
fixed model parameters.

Discussion

In this study, we aimed to review the epidemiological evidence about the impact of
maternal immunization on the effectiveness of pertussis vaccines in infants and to
interpret this evidence using a new mechanistic mathematical model that represented
the effect of blunting on pertussis transmission dynamics. Our review identified four
observational epidemiological studies, all of which had short monitoring times and often
combined with small sample sizes. Most studies suggested a reduced risk of pertussis
after receipt of the first vaccine dose in infants born to mothers immunized during
pregnancy. After receipt of the second or third vaccine dose, however, the estimates were
more heterogeneous and, due to high estimate uncertainty, consistent with a range of
assumptions about the impact of maternal immunization. To interpret these empirical
estimates, we performed a simulation study using an age-structured model of pertussis
transmission. This model predicted that the introduction of maternal immunization was

followed by a transient phase lasting at least a decade, during which the blunting effect
of maternal antibodies could be underestimated. The model-data comparison suggested
that a modest level of blunting could not be ruled out, even though the large uncertainty
in empirical estimates prevented a definitive conclusion. Even in the presence of such
blunting, however, our model predicted that maternal immunization remained effective
at reducing pertussis in unvaccinated newborns. Hence, our results confirm that maternal
immunization is an effective strategy to protect this age group, but suggest it may
eventually result in an infection-control trade-off with older age groups.

Unvaccinated newborns are the demographic most vulnerable to pertussis, both in terms
of infection and hospitalization risks [5],[6],[7]. Our study suggests that, although
maternal blunting may erode the benefits of immunization in infants, it is highly effective
at protecting unvaccinated newborns. Hence, our results support the decision of many
public health authorities to introduce maternal immunization against pertussis, provided
that the main control objective is to protect newborns [8,9]. More generally, given the
vulnerability of newborns to many pathogens, maternal immunization against other
infectious diseases is considered by public health authorities and the pharmaceutical
industry. For example, a new maternal vaccine against RSV recently underwent a
successful phase 2b trial [39]. Aside from pertussis, blunting of infant antibody
concentration following maternal immunization has been demonstrated for many
infections, including diphtheria, tetanus, pneumococcus, meningococcus, tuberculosis,
polio, measles, mumps, and rotavirus [15,17,40,41]. Maternal immunization, therefore,
also appears as a promising strategy to protect newborns against these infections, but
our results suggest the need to monitor its impact on subsequent vaccination of infants
carefully.

One of the main takeaways from our review was the large heterogeneity and uncertainty
of available empirical estimates, emphasizing the urgent need for more research on
maternal blunting. However, if such blunting is confirmed by future evidence, there are
ways to mitigate its impact. Immunity in newborns conferred by maternal antibodies
against pertussis likely wanes quickly, on a timescale of months according to our model.
Given these fast waning rates, delaying infant primary immunization by a few months
might greatly reduce the maternal blunting of infant immunization [17]. Pertussis

immunization schedules vary greatly between countries, with the age at first
immunization of infants typically ranging between two and four months [22], and the
current variation in pertussis immunization schedule can significantly impact the
effectiveness of pertussis immunization in infants [42]. If maternal blunting occurs, our
results suggest that the optimal age at first immunization is governed by a trade-off
between vaccinating too early (with the effect of reducing the susceptibility age window
in newborns but amplifying the impact of blunting in vaccinated infants) and too late
(with the opposite effect). As the costs of infection in unvaccinated newborns likely
exceed those in older age groups, the introduction of maternal immunization may thus
increase the optimal age at first immunization, in all infants or only in those born to
vaccinated mothers. Interestingly, the Dutch public health authorities take a distinct
approach: children from unvaccinated mothers get their first pertussis immunization at
the age of two months, while children from vaccinated mothers get their first dose at
three months [43]. Identifying the optimal pertussis immunization schedule for infants
would be helpful for public health authorities, especially given the vast between-country
variation in pertussis immunization schedules [22,42,44]. Our new model could thus help
future research on optimal vaccine schedules.

After the roll-out of maternal immunization, our model predicted a transient phase
lasting approximately a decade, during which the incidence of pertussis—in both
unvaccinated newborns and vaccinated infants—initially dropped, but then bounced
back and re-increased to reach a new equilibrium. The duration of this transient phase is
consistent with that found in a previous modeling study [45] and may be explained by
the time required for the first cohorts of blunted-vaccinated infants (*i.e.*, born to
vaccinated mothers) to reach primary school age and its associated high contacts. Hence,
reduced transmission from unvaccinated newborns may explain the initial decrease in
incidence across age groups, but this benefit gradually wears off as blunted-vaccinated,
and therefore less well-protected, children age.

From a practical perspective, this transient phase has at least two important implications.
First, the current epidemiological studies had ≤6 years of monitoring, a time frame we
predict is insufficient to capture the long-term consequences of maternal immunization.
Second, a RR of 1 is considered the baseline value indicating that maternal immunization

does not blunt vaccine effectiveness in infants. In the transient phase, however, our model

predicts that the baseline value under a no-blunting scenario starts off close to 0 and

gradually increases to an equilibrium just below 1. This equilibrium value results from

the residual protection from maternal antibodies, which partially compensates for

failures of primary immunization in infants born to vaccinated mothers. These results

suggest that the early empirical estimates of vaccine effectiveness may overestimate the

benefits of maternal immunization, both for newborns and for infants. A testable

prediction of our model, therefore, is that the benefits of maternal immunization

estimated in subsequent studies will be lower than those currently reported, both in

newborns and after the primary series. Note though that the COVID-19 pandemic and its

associated lockdown will have changed the temporal dynamics of RR following maternal

immunization. More broadly, as reflected in some official guidelines for vaccine impact

evaluation [46] and demonstrated for other vaccines such as influenza and

streptococcus, biased estimation of vaccine effectiveness because of transient dynamics

early after vaccine roll-out is likely a more general occurrence.

In addition to the monitoring time, other components of the design of current

epidemiological studies may affect their interpretation. First, as the mothers' decision to

receive Tdap during pregnancy is voluntary and likely related to other socioeconomic

status factors that will affect—and presumably reduce—their infants' risk of pertussis,

the baseline comparability between groups is far from obvious in these observational

studies. Hence, estimates of the effectiveness of maternal immunization may have been

confounded by healthy user bias; interestingly, the only study that controlled for most

characteristics of the mothers [14] had large statistical uncertainty and could not rule out

blunting. In addition to this confounding problem, maternal immunization may prevent

mothers from transmitting pertussis to their infants, an indirect effect that could lead to

underestimating the risk of pertussis and masking the effect of blunting in the group of

infants vaccinated and born to vaccinated mothers (as recognized by some

investigators [11]). Because of these potential biases, current RR estimates may have

been underestimated, and our model predictions regarding the level of blunting may be

conservative.

Our study has several limitations. First, our model was parameterized based on previous estimates in Massachusetts, USA, and may only correctly represent pertussis epidemiology in comparable high-income countries. Second, in the absence of serological correlates of protection for pertussis [28–30], the duration of maternally-derived protection—and in particular how it connects to maternal antibody titers in the infant— is unknown. In our model, this parameter was calibrated to reach empirical estimates of maternal immunization effectiveness in newborns, with an average duration of maternally derived protection at 8.7 months resulting in vaccine effectiveness for newborns close to 80%. Even though sensitivity analyses demonstrated that our main results were robust to variations in this parameter, more accurate estimation will be important to inform future models and predict optimal vaccination schedules. Third, for simplicity, we did not model the direct, protective effect of maternal immunization on mothers—only the indirect effect on their newborns. This direct effect is an additional benefit of maternal immunization, but because in high-income countries the proportion of women giving birth is small relative to the total adult population, it is expected to have a minor epidemiological impact. Fourth, in our simulations, maternal immunization coverage was fixed at 70%, while in real-world settings it is often initially low and gradually increases. However, such temporal variations in immunization coverage are expected to increase the duration of the transient phase and would thus reinforce our conclusions about the unreliability of early empirical estimates.

To conclude, our study shows that maternal immunization is effective at protecting newborns, even when blunting erodes some of its benefits. The degree of blunting, and the extent to which it entails an epidemiological cost in older age groups, can not be known yet, as we predict that the implementation of maternal immunization is followed by a transient phase during which the epidemiological impact of blunting is masked. Hence, current epidemiological studies may be insufficient to rule out blunting or grasp the long-term epidemiological consequences of maternal immunization. Our results, therefore, identify the need for more research to precisely estimate the degree of blunting after primary immunization, if any. More generally, our study supports the use of maternal immunization to reduce pertussis in newborns, but suggests this strategy may be associated with an infection-control trade-off between different age groups.

References

1. Kilgore PE, Salim AM, Zervos MJ, Schmitt HJ. Pertussis: Microbiology, Disease, Treatment, and Prevention. Clin Microbiol Rev. 2016;29: 449–486.

2. Rohani P, Scarpino SV, editors. Pertussis: Epidemiology, Immunology & Evolution. Oxford University Press, Oxford; 2019.

3. Domenech de Cellès M, Magpantay FMG, King AA, Rohani P. The impact of past vaccination coverage and immunity on pertussis resurgence. Sci Transl Med. 2018;10: eaaj1748.

4. Domenech de Cellès M, Magpantay FMG, King AA, Rohani P. The pertussis enigma: reconciling epidemiology, immunology and evolution. Proc Biol Sci B. 2016;283: 20152309.

5. Kandeil W, van den Ende C, Bunge EM, Jenkins VA, Ceregido MA, Guignard A. A systematic review of the burden of pertussis disease in infants and the effectiveness of maternal immunization against pertussis. Expert Rev Vaccines. 2020;19: 621–638.

6. Mbayei SA, Faulkner A, Miner C, Edge K, Cruz V, Peña SA, et al. Severe Pertussis Infections in the United States, 2011–2015. Clin Infect Dis. 2019;69: 218–226.

7. Quinn HE, Comeau JL, S MH, J EE, W CN, Blyth CC, et al. Pertussis disease and antenatal vaccine effectiveness in Australian children. Pediatr Infect Dis J. 2022;41: 180–185.

8. World Health Organization. Pertussis vaccines: WHO position paper – August 2015.

9. Abu-Raya B, Maertens K, Edwards KM, Omer SB, Englund JA, Flanagan KL, et al. Global perspectives on immunization during pregnancy and priorities for future research and development: an international consensus statement. Front Immunol. 2020;11: 1282.

10. Dabrera G, Amirthalingam G, Andrews N, Campbell H, Ribeiro E Sonia Kara, Fry NK, et al. A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 2012–2013. Clin Infect Dis. 2015;60: 333–337.

11. Amirthalingam G, Campbell H, Ribeiro S, Fry NK, Ramsay M, Miller E, et al. Sustained effectiveness of the maternal pertussis immunization program in England 3 years following introduction. Clin Infect Dis. 2016;63: S236–S243.

12. Baxter R, Bartlett J, Fireman B, Lewis E, Klein NP. Effectiveness of vaccination during pregnancy to prevent infant pertussis. Pediatrics. 2017;139: e20164091.

13. Skoff TH, Blain AE, Watt J, Scherzinger K, McMahon M, Zansky SM, et al. Impact of the US Maternal Tetanus, Diphtheria, and Acellular Pertussis Vaccination Program on Preventing Pertussis in Infants <2 Months of Age: A Case-Control Evaluation. Clin Infect Dis. 2017;65: 1977–1983.

14. Rowe SL, Leder K, Perrett KP, Romero N, Nolan TM, Stephens N, et al. Maternal
vaccination and infant influenza and pertussis. Pediatrics. 2021;148: e2021051076.

15. Albrecht P, A EF, Saltzman EJ, S K. Persistence of maternal antibody in infants
beyond 12 months: mechanism of measles vaccine failure. J Pediatr. 1977;91: 715–
717.

16. Bento AI, King AA, Rohani P. Maternal pertussis immunisation: clinical gains and
epidemiological legacy. Euro Surveill. 2017;22: 30510.

17. Voysey M, Kelly DF, Fanshawe TR, Sadarangani M, O'Brien KL, Perera R, et al. The
influence of maternally derived antibody and infant age at vaccination on infant
vaccine responses: an individual participant meta-analysis. JAMA Pediatr. 2017;17:
637–646.

18. Barug D, Pronk P, van Houten MA, Versteegh FGA, Knol MJ, van de Kassteele J, et al.
Maternal pertussis vaccination and its effects on the immune response of infants
aged up to 12 months in the Netherlands: an open-label, parallel, randomised
controlled trial. Lancet Infect Dis. 2019;19: 392–401.

19. Abu-Raya B, Maertens K, Munoz FM, Zimmermann P, Curtis N, Halperin SA, et al.
The effect of Tetanus-Diphtheria-Acellular-Pertussis immunization during
pregnancy on infant antibody responses: individual-participant data meta-analysis.
Front Immunol. 2021;12: 689394.

20. Caboré RN, Maertens K, Dobly A, Leuridan E, Van Damme P, Huygen K. Influence of
maternal vaccination against diphtheria, tetanus, and pertussis on the avidity of
infant antibody responses to a pertussis containing vaccine in Belgium. Virulence.
2017;8: 1245–1254.

21. Zimmermann P, Perrett KP, L MN, Donath S, Ritz N, van der Klis FRM, et al. The
effect of maternal immunisation during pregnancy on infant vaccine responses.
EClinicalMedicine. 2019;13: 21–30.

22. Perkins TA, Tran QM. Timing is everything when it comes to pertussis vaccination.
Lancet Infect Dis. 2022;22: 158–159.

23. Domenech de Cellès M, Rohani P, King AA. Duration of Immunity and Effectiveness
of Diphtheria-Tetanus-Acellular Pertussis Vaccines in Children. JAMA Pediatr.
2019;173: 588–594.

24. McLean AR, Anderson RM. Measles in developing countries Part I. Epidemiological
parameters and patterns. Epidemiol Infect. 1988;100: 111–133.

25. McLean AR, Blower SM. Imperfect vaccines and herd immunity to HIV. Proc R Soc B
Biol Sci. 1993;253: 9–13.

26. Healy CM, Rench MA, Swaim LS, Timmins A, Vyas A, Sangi-Haghpeykar H, et al.
Kinetics of maternal pertussis-specific antibodies in infants of mothers vaccinated
with tetanus, diphtheria and acellular pertussis (Tdap) during pregnancy. Vaccine.
2020;38: 5955–5961.

27. Oguti B, Ali A, Andrews N, Barug D, Anh Dang D, Halperin SA, et al. The half-life of
maternal transplacental antibodies against diphtheria, tetanus, and pertussis in
infants: an individual participant data meta-analysis. Vaccine. 2022;40: 450–458.

28. Van Rie A, Wendelboe AM, Englund JA. Role of maternal pertussis antibodies in
infants. Pediatr Infect Dis J. 2005;24: S62–S65.

29. Diavatopoulos DA, Mills KHG, Kester KE, Kampmann B, Silerova M, Heininger U, et
al. PERISCOPE: road towards effective control of pertussis. Lancet Infect Dis.
2019;19: e179–e186.

30. Chen Z, Liu X, Zhang Y, Peng X, Zhang N, Chen N, et al. Evaluation of serum anti-
pertussis toxin IgA antibodies for the diagnosis of Bordetella pertussis infection in
young children. J Infect Public Health. 2023;16: 1167–1173.

31. Amirthalingam G, Campbell H, Ribeiro S, Stowe J, Tessier E, Litt D, et al.
Optimization of Timing of Maternal Pertussis Immunization From 6 Years of
Postimplementation Surveillance Data in England. Clin Infect Dis. 2023;8: e1129–
e1139.

32. Farrington CP. Estimation of vaccine effectiveness using the screening method. Int J
Epidemiol. 1993;22: 742–746.

33. Minodier L, Blanchon T, Souty C, Turbelin C, Leccia F, Varesi L, et al. Influenza
vaccine effectiveness: best practice and current limitations of the screening method
and their implications for the clinic. Expert Rev Vaccines. 2014;13: 1039–1048.

34. He D, Ionides EL, King AA. Plug-and-play inference for disease dynamics: measles in
large and small populations as a case study. J R Soc Interface. 2010;7: 271–283.

35. King AA, Nguyen D, Ionides EL. Statistical Inference for Partially Observed Markov
Processes via the R Package pomp. J Stat Softw. 2016;69: 1–43.

36. R Core Team. R: A Language and Environment for Statistical Computing. Vienna,
Austria: R Foundation for Statistical Computing; 2022. Available: https://www.R-
project.org/

37. Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social contacts
and mixing patterns relevant to the spread of infectious diseases. PLoS Med.
2008;5: e74.

38. Béraud G, Kazmercziak S, Beutels P, Levy-Bruhl D, Lenne X, Mielcarek N, et al. The
French Connection: The First Large Population-Based Contact Survey in France
Relevant for the Spread of Infectious Diseases. PLoS One. 2015;10: e0133203.

39. Simões EAF, Center KJ, Tita ATN, Swanson KA, Radley D, Houghton J, et al. Prefusion
F protein–based respiratory syncytial virus immunization in pregnancy. N Engl J
Med. 2022;386: 1615–1626.

40. Mawa PA, Nkurunungi G, Egesa M, Webb EL, Smith SG, Kizindo R, et al. The impact
of maternal infection with Mycobacterium tuberculosis on the infant response to
bacille Calmette–Guérin immunization. Philos Trans R Soc Lond B Biol Sci.

2015;3017: 20140137.

41.   Gans HA, Arvin AM, Galinus J, Logan L, DeHovitz R, Maldonado Y. Deficiency of the
Humoral Immune Response to Measles Vaccine in Infants Immunized at Age 6
Months. JAMA. 1998;280: 527–532.

42.   Paireau J, Guillot S, Aït El Belghiti F, Matczak S, Trombert-Paolantoni S, Jacomo V, et
al. Impact of vaccine schedule change on pertussis epidemiology in France: a
modelling and serological study. Lancet Infect Dis. 2022;22: 265–273.

43.   Rijksinstituut Voor Volksgezondheid en Milieu. In: Dutch National Immunisation
Programme [cited 7 Mar 2023]. Available at:
https://rijksvaccinatieprogramma.nl/english

44.   Riolo MA, Rohani P. Combating pertussis resurgence: One booster vaccination
schedule does not fit all. Proc Natl Acad Sci U S A. 2015;112: E472–E477.

45.   Bento AI, Rohani P. Forecasting Epidemiological Consequences of Maternal
Immunization. Clin Infect Dis. 2016;63: S205–S212.

46.   World Health Organization. Measuring impact of streptococcus pneumoniae and
haemophilus influenzae type b conjugate vaccination. 2012. Available at:
https://apps.who.int/iris/handle/10665/75835

Acknowledgements

We thank the useful discussions and feedback from Andrew Tredennick (University of

Georgia, USA), Christian Gunning (University of Georgia, USA), Denis Macina (Sanofi

Pasteur, France), Laurent Coudeville (Sanofi Pasteur, France), and Edward Thommes

(Sanofi Pasteur, Canada).

Data Reproducibility

All R scripts are currently available at:

https://drive.google.com/drive/folders/1-tT3XaPYwPbviXe1OB7_hvN8SSYe9HYJ,   and

will be made freely available upon publication via Edmond, the Open Data Repository of

the Max Planck Society.

Potential conflict of interests

Prof. Pejman Rohani received funding from Sanofi France for another separate project.

Fig. 1 Prisma flow chart of the literature search for empirical estimates of the relative risk

(RR) of contracting pertussis following maternal immunization in children who had

received at least one dose of infant primary immunization.

Fig. 2 Overview of the results from empirical epidemiologic studies of the relative risk of contracting pertussis in infants from vaccinated mothers relative to those of unvaccinated mothers during infant primary immunization. A value of 0 implies complete protection following maternal immunization, and a value of 1 indicates an equal risk of contracting pertussis between infants from vaccinated versus unvaccinated mothers. The literature search protocol is shown in Fig. 1, and the data are available in Table S1. The two lines for the UK 3 years study represent two estimates of maternal immunization coverage. References: Australia 2yrs [14], California 3yrs [12], UK 3yrs [11], and UK 6yrs [31].

Fig. 3 Illustration of honeymoon effects and transient susceptible dynamics following the start of infant immunization (vertical dashed line at time = 0 years) and maternal immunization without blunting (vertical dashed line at time = 100 years) showing (A) pertussis incidence and (B) the fraction susceptible for each age class from one stochastic simulation.

Fig. 4 Model predictions of the consequences of maternal immunization and blunting for

pertussis incidence in (A) unvaccinated newborns (aged 0–2 mo) and (B) vaccinated

infants (aged 3–18 mo, after receipt of primary immunization). For this age class, during

the transient phase after maternal immunization, pertussis incidence is at first mostly

driven by (C) infants from unvaccinated mothers until (D) pertussis incidence is most

abundant in infants from vaccinated mothers. Panel (D) is consistent with the PCV-term

in the RR equation (see methods, [32]). Solid lines show the median incidence of 100

simulations and shaded areas represent the 95% CI. In this figure, all immunization

coverages were set at 70%, which is close to the mean observed values in empirical

studies (e.g., Table S1). Note the different *y*-axis between panels.

Fig. 5 Temporal dynamics of the risk of contracting pertussis in (A) unvaccinated newborns and (B, C) vaccinated infants from vaccinated mothers relative to those of unvaccinated mothers. A value of 0 shows 100% protection due to maternal immunization, a value of 1 illustrates an equal risk of contracting pertussis in infants from vaccinated mothers relative to unvaccinated mothers, and any value above 1 shows an increased risk, with for example a value of 2 indicating a two-fold increased risk. (A, B) Solid lines show the median RR of 100 simulations and shaded areas show 95% CI resulting from demographic stochasticity across simulations. (C) Comparison between the results from model simulations (gradient red diamonds) and the empirical studies (colored dots). In simulations, vertical lines show 95% CI due to demographic stochasticity and observation uncertainty, resulting from the partial sampling of the population with sample sizes matching those from empirical studies in Fig. 2 (Table S1).